Primary cutaneous T-cell lymphoma: Review and current concepts

Journal of Clinical Oncology

Volumn 18, Issue 15, 2000, Pages 2908-2925

  Siegel, Richard S ^a   Pandolfino, Tomi ^a   Guitart, Joan ^a   Rosen, Steven ^a   Kuzel, Timothy M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GLUCOCORTICOID; HYBRID PROTEIN; HYPERICIN; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; METHOTREXATE; MONOCLONAL ANTIBODY; PENTOSTATIN; PURINE DERIVATIVE; RETINOID; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

BASAL CELL CARCINOMA; BONE MARROW SUPPRESSION; CLINICAL FEATURE; DELAYED HYPERSENSITIVITY; DRUG INDUCED DISEASE; EDEMA; ELECTRON BEAM; ERYTHEMA; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PUVA; REVIEW; SKIN ALLERGY; SKIN LYMPHOMA; SQUAMOUS CELL CARCINOMA; STAGING; SURVIVAL RATE; T CELL LYMPHOMA; TELANGIECTASIA; ULTRAVIOLET B RADIATION;

EID: 0033866959     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.15.2908     Document Type: Review

References (129)

1. Classification of primary cutaneous lymphomas: Historical overview and perspectives
2. EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer
3. Mycosis fungoides in the United States: Increasing incidence and descriptive epidemiology
4. Mycosis fungoides in relation to environmental exposures and immune response: A case-control study
5. A case-control study of possible causative factors in mycosis fungoides
6. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma
7. Deleted HTLV-I provirus in blood and cutaneous lesions of patients with mycosis fungoides
8. The role of human T-cell lymphotropic viruses (HTLV-I and II) in cutaneous T-cell lymphomas
9. Absence of human T-lymphotropic virus type I in Japanese patients with cutaneous T-cell lymphoma
10. No evidence of HTLV-I proviral integration in lymphoproliferative disorders associated with cutaneous T-cell lymphoma
11. HHV-8 in lymphoproliferative lesions in skin
12. Lack of evidence on HHV-8 in mature T-cell lymphoproliferative disorders
13. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V-beta gene expansion
14. Interleukin-7 is a growth factor for Sezary lymphoma cells
15. Cutaneous lymphoproliferation and lymphomas on interleukin 7 transgenic mice
16. Familial occurrence of cutaneous T-cell lymphoma: A case report of monozygotic twin sisters
17. Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides/Sezary syndrome
18. Chromosome aberrations, spontaneous SCE, and growth kinetics in PHA-stimulated lymphocytes of five cases with Sezary syndrome
19. Molecular analysis of cutaneous B- and T-cell lymphomas
20. The immunopathogenesis of cutaneous T-cell lymphoma
21. Epidermal interferon-γ inducible protien-10 (IP-10) and monokine induced by γ-interferon (Mig) but not IL-8 mRNA expression is associated with epidermotropism in cutaneous T-cell lympomas
22. Tumor necrosis factor-α and interferon-γ, but not HTLV-I tax are likely factors in the epidermotropism of cutaneous T-cell lymphoma via induction of interferoninducible protein-10
23. Epidemiology and clinical manifestations of cutaneous T-cell lymphoma
24. Population-based estimate of survival and determinants of prognosis in patients with mycosis fungoides
25. Sezary syndrome: A clinicopathologic study of 39 cases
26. Evaluation of circulating malignant cells provides prognostic information in cutaneous T-cell lymphoma
27. Sezary syndrome: Diagnosis, prognosis, and critical review of treatment options
28. Mycosis fungoides and Sezary syndrome
29. Mycosis fungoides and the Sezary syndrome: A review of pathogenesis, diagnosis, and therapy
30. Quantitative electron microscope comparison of lymphocyte nuclear contours in mycosis fungoides and in benign infiltrates in the skin
31. The value of nuclear contour index in the diagnosis of mycosis fungoides
32. T-cell technology in the diagnosis and management of cutaneous T-cell lymphoma
33. Clonal rearrangements of T-cell receptor genes in mycosis fungoides and dermatopathic lymphadenopathy
34. Diagnostic value of T-cell receptor beta gene rearrangement analysis on peripheral blood lymphocytes of patients with erythroderma
35. A new polymerase chain reaction-based method for the detection of T-cell clonality in patients with possible cutaneous T-cell lymphoma
36. T-cell receptor gene analysis in the diagnosis of Sezary syndrome
37. Demonstration of clonal T cells in the peripheral blood of patients with primary cutaneous T-cell lymphoma
38. Prognostic clinicopathologic factors in cutaneous T-cell lymphoma
39. Epidermal Langerhans' cell densities influence survival in mycosis fungoides and Sezary syndrome
40. CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides
41. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sezary syndrome
42. Clinical stage IA (limited patch and plaque) mycosis fungoides: A long-term outcome analysis
43. Prognosis in cutaneous T-cell lymphoma by skin stage: Long-term survival in 489 patients
44. Prognostic factors in Sezary syndrome: A multivariate analysis of clinical, hematological and immunologic features
45. Cytologic transformation in cutaneous T-cell lymphoma: A clinicopathologic entity associated with poor prognosis
46. Transformation of mycosis fungoides/Sezary syndrome: Clinical characteristics and prognosis
47. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides
48. Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma
49. Photochemotherapy (PUVA) in the pretumor stage of mycosis fungoides: A report from the Scandinavian Mycosis Fungoides Study Group
50. Photochemotherapy for mycosis fungoides: A clinical and histological study
51. Photochemotherapy in mycosis fungoides: A study of 73 patients
52. Photochemotherapy for cutaneous T-cell lymphoma
53. Treatment of mycosis fungoides with photochemotherapy (PUVA): Long-term follow-up
54. Acute myeloid leukemia following psoralen with ultraviolet A therapy: A fluorescence in situ hybridization study
55. Mycosis fungoides: Management with topical nitrogen mustard
56. Topical mechlorethamine therapy for early stage mycosis fungoides
57. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T-cell lymphoma
58. Ointment-based mechlorethamine treatment for mycosis fungoides
59. Topical carmustine (BCNU) for patch/plaque mycosis fungoides
60. Electron beam treatment for cutaneous T-cell lymphoma
61. Total skin electron beam radiation therapy for mycosis fungoides
62. Electron-beam therapy for mycosis fungoides: The Stanford University experience
63. Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma
64. Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma
65. Radiation therapy for skin cancer near the eye: Kilovoltage x-rays versus electrons
66. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy
67. Photopheresis update
68. Extracorporeal photopheresis in Sezary syndrome: No significant effect in the survival of 44 patients with a peripheral blood T-cell clone
69. Chemotherapy for mycosis fungoides and the Sezary syndrome
70. Cutaneous T-cell lymphomas
71. Low-dose methotrexate for the Sezary syndrome
72. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma
73. An investigation of 2'-deoxycoformycin in the treatment of cutaneous T-cell lymphoma
74. Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease
75. Treatment of cutaneous T-cell lymphoma with 2'-deoxycoformycin (Pentostatin)
76. The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas
77. Interferon alfa-2a in the treatment of cutaneous T-cell lymphoma
78. Interferon in the treatment of cutaneous T-cell lymphoma
79. Acrocyanosis induced by interferon-alpha 2a
80. Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA
81. Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression
82. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome
83. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma
84. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides)
85. 13-cis-retinoic acid in mycosis fungoides
86. Interleukin-2 fusion protein: An investigational therapy for interleukin-2 receptor expressing malignancies
87. 389IL-2 fusion toxin in mycosis fungoides
88. 389il-2 (Ontak) for the treatment of mycosis fungoides
89. Interleukin-1alpha increases the preferential cytotoxicity of an interleukin-2-diptheria toxin fusion protein against neoplastic lymphocytes from patients with the Sezary syndrome compared to normal lymphocytes
90. Roferon-A (interferon alpha 2a) combined with Tegison (etretinate) for treatment of cutaneous T-cell lymphomas
91. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-α2a and etretinate
92. Retinoids and systemic chemotherapy in cases of advanced mycosis fungoides: A report from the Scandinavian Mycosis Fungoides Group
93. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma
94. The potential role of interleukin-12 in cutaneous T-cell lymphoma
95. Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody
96. A patient with plaque-stage mycosis fungoides has successfully been treated with long-term administration of IFN-gamma and has been in complete remission for more than six years
97. Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lympboma
98. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study
99. Antiidiotype (Ab2) vaccine therapy for cutaneous T-cell lymphoma
100. Photoactivated hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal, transformed, and malignant T-lymphocytes: Implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders
101. Spectrum of primary cutaneous CD30(Ki-1)-positive lympboproliferative disorders: A proposal for classification and guidelines for management and treatment
102. Primary cutaneous CD30-positive large cell lymphoma: Definition of a new type of cutaneous lymphoma with a favorable prognosis - A European multi-center study of 47 patients
103. Primary cutaneous T-cell lymphoma: Clinicopathological features and prognostic parameters of 35 cases other than mycosis fungoides and CD30-positive large cell lymphoma
104. Subcutaneous panniculitis-like T-cell lymphoma
105. Parapsoriasis
106. The nosology of parapsoriasis
107. If small plaque (digitate) parapsoriasis is a cutaneous T-cell lymphoma, even an 'abortive' one, it must be mycosis fungoides!
108. Cutaneous lymphomas consist of nosologically different entities including mycosis fungoides and small plaque parapsoriasis
109. Reticuloses
110. Parapsoriasis and mycosis fungoides: The Northwestern University experience, 1970 to 1985
111. Follicular mucinosis: Histopathologic review of 33 cases
112. Follicular mucinosis associated with mycosis fungoides
113. Localized and disseminated pagetoid reticulosis
114. Woringer-Kolopp disease (pagetoid reticulosis): Four cases with histopathologic, ultrastructural, and immunohistologic observations
115. Disseminated pagetoid reticulosis: Response to bath PUVA
116. Granulomatous slack skin: Report of three patients with an updated review of the literature
117. Lymphomatoid papulosis update: A historical perspective
118. Lymphomatoid papulosis
119. Lymphomatoid papulosis: A T-cell dyscrasia with a propensity to transform into malignant lymphoma
120. Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone
121. Differentiation between actinic reticuloid and cutaneous T-cell lymphoma by T-cell receptor gamma gene rearrangement analysis and immunophenotyping
122. Actinic reticuloid: A clinical, photobiologic, and follow-up study of 16 patients
123. Cutaneous pseudo-T-cell lymphomas: A clinicopathologic study of 20 patients
124. Drug-induced pseudolymphomatous skin reactions
125. Immunophenotyping and gene rearrangement analysis provide additional criteria to differentiate between cutaneous T-cell lymphomas and pseudo-T-cell lymphomas
126. Analysis of clonality of atypical lymphoid infiltrates associated with drug therapy by PCR/DGGE
127. Clinical and histologic spectrum of human T-cell lymphotropic virus type I-associated lymphoma involving the skin